A Phase III Multicenter Clinical Trial of Analatro®[Antivenin Latrodectus (Black Widow) Equine Immune F9(ab)2] in Patients with Systemic Latrodectism


14255

A Phase III Multicenter Clinical Trial of Analatro®[Antivenin Latrodectus (Black Widow) Equine Immune F9(ab)2] in Patients with Systemic Latrodectism

Emergency Medicine

Holstege Christopher,

Staff Flyers not intended for distribution to patients.

Emergency Medicine-Nontransport

Adult
Child





None None